Growth Metrics

Emergent BioSolutions (EBS) Asset Writedowns and Impairment (2016 - 2019)

Historic Asset Writedowns and Impairment for Emergent BioSolutions (EBS) over the last 11 years, with Q2 2024 value amounting to $27.2 million.

  • Emergent BioSolutions' Asset Writedowns and Impairment fell 9113.14% to $27.2 million in Q2 2024 from the same period last year, while for Jun 2025 it was $27.2 million, marking a year-over-year decrease of 9185.38%. This contributed to the annual value of $27.2 million for FY2024, which is 9113.14% down from last year.
  • As of Q2 2024, Emergent BioSolutions' Asset Writedowns and Impairment stood at $27.2 million, which was down 9113.14% from $306.7 million recorded in Q2 2023.
  • In the past 5 years, Emergent BioSolutions' Asset Writedowns and Impairment ranged from a high of $306.7 million in Q2 2023 and a low of $27.2 million during Q2 2024